More about Concord Biotech Limited
Fundamentals for Concord Biotech Limited
Regulatory Filings for Concord Biotech Limited
From Cost Center to Strategic Core: The Top 10 Trends Transforming Finance in 2026
CFOs Seize the Tech Purse Strings: How 2026 Budgets Are Fueling the AI Transformation
From Agentic AI to Tokenized Assets: The Fintech Trends Reshaping Financial Services
Forex Focus: How a Weakening Indian Rupee Could Reshape Markets in Q1 2026
Technicals for Concord Biotech Limited
Price Summary
On 2026-02-27, Concord Biotech Limited's shares started at 1242.9, peaked at 1274.4, bottomed out at 1215.0, and ended -1.79% down at 1220.6, with 535622 shares traded.The stock reached its highest price of 2130.4 and lowest price of 1076.1 over the last 52 weeks.
Based on recommendations from 6 analysts, the future price of CONCORDBIO is expected to range from 1170.0 to 1680.0, with an average price expectation around 1426.6666.
Technicals
Support and Resistance: The price for CONCORDBIO at 1220.6 is supported by the 1109.0 level and faces resistance at 1360.6. This range indicates key levels where the price may find buyers near 1109.0 and sellers near 1360.6, defining a trading range.Aroon: The AROON is currently in a neutral position, offering no clear indication of movement up or down. This suggests that the market may be experiencing a period of equilibrium, with no strong trend in play.
Bol. Bands: The BOLL BANDS is currently in a neutral position, offering no clear indication of movement up or down. This suggests that the market may be experiencing a period of equilibrium, with no strong trend in play.
Parabolic SAR: The PSAR continues its bullish outlook, reinforcing a crucial support level that may help sustain the current upward trend. This support suggests that the market is likely to continue climbing, with the bullish momentum remaining strong.
Stochastic: The STOCHASTIC is in a neutral stance, with no clear signals for movement up or down. This neutral position indicates a potential period of consolidation or uncertainty in the market.
Tripple Moving Agerage: The Tripple MOVING AVG is currently in a neutral position for Concord Biotech Limited, offering no clear guidance on whether the market is likely to move up or down. This neutral stance suggests that further observation may be necessary before a trend becomes apparent.
Understanding a company's fundamentals—such as revenue, earnings, and debt levels—provides a solid foundation for analyzing its technical performance. Similarly, knowledge of the industry, including key competitors and market trends, is critical. Combining this fundamental analysis with technical indicators like stock charts, moving averages, and trading volume enables a more comprehensive approach to evaluating the company's overall health and potential future performance.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
Understanding Divergent House Price Movements Worldwide
The 2026 Tariff Tipping Point: When Trade Policy Reaches the Consumer
From Caracas to Commodities: The Market Impact of U.S.–China Friction